Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03567057 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
A Phase 3 study, sponsored by Adamas Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 424
- Enrollment target
NCT03567057 is a Phase 3 study that has completed, run by Adamas Pharmaceuticals. The registered enrollment target is 424 participants.
The verdict
NCT03567057, a Phase 3 study, has completed, sponsored by Adamas Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 424 participants
- Enrollment target
Study Summary
This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
Interventions
- DRUG ADS-5102, 274 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2021-04-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03567057
The ClinicalTrials.gov registry entry for NCT03567057 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 424 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adamas Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADS-5102, 274 mg is the first listed.
NCT03567057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03567057 about?
NCT03567057 is a clinical study titled "A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment". This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
What is the current status of trial NCT03567057?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 424 participants. The study started on 2018-07-18. Estimated completion is 2021-04-18.
What interventions are being tested in trial NCT03567057?
The interventions under investigation include: ADS-5102, 274 mg (DRUG).
Who is sponsoring clinical trial NCT03567057?
This trial is sponsored by Adamas Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.